Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis.
Ersi Voskaridou(Laiko General Hospital of Athens), Evangelos Terpos(National and Kapodistrian University of Athens), Lito Antoniadou, Ioannis Papassotiriou(National and Kapodistrian University of Athens), Eleni Stoupa, Kostas Konstantopoulos(National and Kapodistrian University of Athens), Evangelos Premetis
PubMed
June 1, 2006
Cited by 62
Related Papers
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
|Journal of Clinical Oncology|2010|409
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
|Leukemia|2017|356
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320